176 related articles for article (PubMed ID: 31374302)
21. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome.
Pielop JA; Brownell I; Duvic M
Int J Dermatol; 2003 Feb; 42(2):116-22. PubMed ID: 12708999
[TBL] [Abstract][Full Text] [Related]
22. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
23. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
24. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.
Herro E; Dicaudo DJ; Davis MD; Weaver AL; Swanson DL
J Am Acad Dermatol; 2009 Aug; 61(2):271-5. PubMed ID: 19481294
[TBL] [Abstract][Full Text] [Related]
25. The different faces of mycosis fungoides: results of a single-center study.
Sidiropoulou P; Nikolaou V; Marinos L; Voudouri D; Komini E; Economidi A; Rigopoulos D; Stratigos A
Int J Dermatol; 2020 Mar; 59(3):314-320. PubMed ID: 31782525
[TBL] [Abstract][Full Text] [Related]
26. Risk of Multiple Primary Cancers in Patients With Merkel Cell Carcinoma: A SEER-Based Analysis.
Eid E; Maloney NJ; Cai ZR; Zaba LC; Kibbi N; John EM; Linos E
JAMA Dermatol; 2023 Nov; 159(11):1248-1252. PubMed ID: 37703005
[TBL] [Abstract][Full Text] [Related]
27. A registry-based case-control study of mycosis fungoides.
Weinstock MA
Ann Epidemiol; 1991 Nov; 1(6):533-9. PubMed ID: 1669533
[TBL] [Abstract][Full Text] [Related]
28. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.
Schonfeld SJ; Morton LM; Berrington de González A; Curtis RE; Kitahara CM
Cancer Epidemiol; 2020 Feb; 64():101664. PubMed ID: 31884334
[TBL] [Abstract][Full Text] [Related]
29. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
30. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
Rihani R; Bazzeh F; Faqih N; Sultan I
Cancer; 2010 Sep; 116(18):4385-94. PubMed ID: 20549819
[TBL] [Abstract][Full Text] [Related]
31. Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study.
Goyal A; O'Leary D; Goyal K; Rubin N; Bohjanen K; Hordinsky M; Chen ST; Duncan LM; Pongas G; Lazaryan A
J Am Acad Dermatol; 2020 Mar; 82(3):736-738. PubMed ID: 31238085
[No Abstract] [Full Text] [Related]
32. [Comparison of the incidence and trends of hematologic malignancies between Japan and the United States].
Chihara D; Ito H; Matsuo K
Rinsho Ketsueki; 2015 Apr; 56(4):366-74. PubMed ID: 25971266
[TBL] [Abstract][Full Text] [Related]
33. Risk of second malignancy after cutaneous T-cell lymphoma.
Kantor AF; Curtis RE; Vonderheid EC; van Scott EJ; Fraumeni JF
Cancer; 1989 Apr; 63(8):1612-5. PubMed ID: 2924268
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population.
Sherman S; Kremer N; Dalal A; Solomon-Cohen E; Berkovich E; Noyman Y; Ben-Lassan M; Levi A; Pavlovsky L; Prag Naveh H; Hodak E; Amitay-Laish I
Acta Derm Venereol; 2020 Dec; 100(19):adv00346. PubMed ID: 33241425
[TBL] [Abstract][Full Text] [Related]
35. Cervical cancer survivors at increased risk of subsequent tobacco-related malignancies, United States 1992-2008.
Underwood JM; Rim SH; Fairley TL; Tai E; Stewart SL
Cancer Causes Control; 2012 Jul; 23(7):1009-16. PubMed ID: 22588679
[TBL] [Abstract][Full Text] [Related]
36. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
Mo X; Zhou M; Yan H; Chen X; Wang Y
Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
[TBL] [Abstract][Full Text] [Related]
37. Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program.
Vakharia PP; Kelm RC; Orrell KA; Patel KR; Singam V; Ali Y; Rastogi S; Yousif R; Rangel SM; West DP; Nardone B
Int J Dermatol; 2020 Apr; 59(4):463-468. PubMed ID: 31971260
[TBL] [Abstract][Full Text] [Related]
38. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
Donin N; Filson C; Drakaki A; Tan HJ; Castillo A; Kwan L; Litwin M; Chamie K
Cancer; 2016 Oct; 122(19):3075-86. PubMed ID: 27377470
[TBL] [Abstract][Full Text] [Related]
39. Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program.
Kutsenko A; Berrington de Gonzalez A; Curtis RE; Rajaraman P
Cancer Causes Control; 2014 Jun; 25(6):659-68. PubMed ID: 24682745
[TBL] [Abstract][Full Text] [Related]
40. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
